TenJet Patient Registry
The TenJet Patient Registry will help us systematically gather and analyze data to understand how effective TenJet is in treating chronic tendinopathy in the elbow, hip, and shoulder.Read More
First-of-Its-Kind Selective Tissue Removal Patent Grant
HydroCision Inc. announced that the U.S. Patent and Trademark Office has issued a new patent, No. 11,278,305, titled "Selective Tissue Removal Treatment Device," for their TenJet device. TenJet is believed to be the first patented device allowing for the targeted removal of tendon tissue.
The patent covers the application of HydroCision's FluidJet technology for the treatment of chronic tendon pain. TenJet's tissue selectivity feature allows removal of pathologic tendon tissue while preserving adjacent healthy tendon, enabling quicker and less painful post-procedure rehabilitation.
HydroCision™ Congratulates PROCEPT® BioRobotics, for Advancing the Field of Minimally Invasive Tissue Aquablation™
HydroCision Inc., a medical device company that pioneered high velocity, heat-free, FluidJet™ technology for surgical resection, congratulates PROCEPT BioRobotics on the recent closing of its upsized initial public offering.
HydroCision is proud to have licensed its technology to PROCEPT BioRobotics and is inspired by its success. Through such strategic agreements and its own research and development efforts, HydroCision is uncovering the potential of its technology to address unmet needs across multiple clinical areas.
HydroCision® Announces Global Licensing Agreement with PROCEPT BioRobotics, Providing Access to its Proprietary Pump Cartridge Technology
Boston, March 26, 2019 - HydroCision, a pioneer in the use of high velocity water jet technology for the minimally invasive treatment of musculoskeletal, spine and wound care conditions, today announced it has provided an exclusive worldwide license of its pump cartridge technology to PROCEPT BioRobotics for use in Urology.
Under the license agreement, HydroCision will receive a one-time upfront payment from PROCEPT BioRobotics. Specific payment terms are confidential and were not disclosed.
HydroCision® Appoints Medical Device Executive with Global Commercial and Market Development Experience as New CEO
BOSTON, March 5, 2019 -- HydroCision, a pioneer in the use of high velocity water jet technology for the minimally invasive treatment of musculoskeletal, spine and wound care conditions, today announced the appointment of Alain Tranchemontagne as Chief Executive Officer (CEO).
"We are delighted to have Alain spearhead the next growth chapter in HydroCision's future," said John Schulte, HydroCision's newly appointed Chairman of the Board. "The Board was impressed with Alain's proven track record at major medical device companies, his leadership and market development experience, as well as his passion and energy to broaden the use of our patented, proprietary technology."
HydroCision Touts Study Results For Herniated Disk Treatment
For the last two-and-a-half years since a group of investors took over control of Hydrocision Inc., the medical device company has been focused on a minimally-invasive way to treat lower back and leg pain due to herniated disks. Now, it hopes a recently-published study will helps establish its products’ effectiveness and spread the word about the treatment in the U.S.Read More
HydroCision Announces Reults from a Newly Published, Multi-Center Study Demonstrating 94% Improvement in Back & Leg Pain
NORTH BILLERICA, Mass., January 11, 2013 -- HydroCision Inc., a privately held medical device company, today announced the results of a multi-center study published in the January edition of the Internet Spine Journal demonstrating a 94% improvement in back and leg pain for patients receiving Hydrodiscectomy. It has been estimated that more than 60 million people worldwide experience chronic lower back and leg pain, which is often caused by herniated or 'bulging' spinal discs, a leading cause of disability among Americans less than 45 years of age. The study consisted of a retrospective analysis of 50 patients who received the Hydrodiscectomy procedure after failing conservative treatment such as pain medications, physical therapy and epidural steroid injections.Read More